-transparent.png){kind=logo}
The pharmacokinetics of vindesine were investigated in five patients with advanced cancer who were described by a triphasic serum decay curve compatible with a three-compartment open mammillary model. Serum half-lives were 2 min, 50 min, and 24 h for the fast, middle, and slow phases, respectively. The volume of the central compartment approximated the plasma volume in all patients studied. Distribution occurred quickly into a superficial tissue compartment in fairly rapid equilibrium with the plasma compartment, and also into a deep tissue compartment with slower redistribution to the central compartment. The large apparent volume of distribution and long elimination half-live suggest extensive tissue sequestration or delayed excretion of the drug in man. The slightly increased serum half-life of vindesine compared with published results for vinblastine may account for the greater degree and longer duration of marrow suppression seen clinically with vindesine.
R L Nelson, and
R W Dyke, and
M A Root
January 1985,
Cancer treatment reports,
R L Nelson, and
R W Dyke, and
M A Root
November 1984,
European journal of cancer & clinical oncology,
R L Nelson, and
R W Dyke, and
M A Root
January 1984,
Cancer chemotherapy and pharmacology,
R L Nelson, and
R W Dyke, and
M A Root
September 1991,
Gan to kagaku ryoho. Cancer & chemotherapy,
R L Nelson, and
R W Dyke, and
M A Root
August 1977,
Cancer research,
R L Nelson, and
R W Dyke, and
M A Root
January 1984,
Cancer chemotherapy and pharmacology,
R L Nelson, and
R W Dyke, and
M A Root
January 1981,
Cancer treatment reports,
R L Nelson, and
R W Dyke, and
M A Root
January 1982,
Medical and pediatric oncology,
R L Nelson, and
R W Dyke, and
M A Root
November 1996,
Cancer treatment reviews,
R L Nelson, and
R W Dyke, and
M A Root
January 1983,
Cancer chemotherapy and pharmacology,
